Hormonal
Short-acting GLP-1 RAs cause more pronounced delays in gastric emptying than long-acting agents, although long-acting agents may still pose aspiration risks due to residual effects depending on dose and treatment duration.
Know which GLP-1 medication you take. Short-acting drugs (like Byetta or Trulicity's short-acting cousin) tend to slow your stomach more than long-acting ones (like Ozempic or Mounjaro). However, even long-acting drugs can keep food in your stomach if you took a dose recently. Always tell your surgical team exactly when you took your last dose.
Short-acting GLP-1 RAs cause more pronounced delays in gastric emptying, whereas long-acting agents may exert residual effects depending on dose and treatment duration.
Why this rating
Based on pharmacological descriptions and comparative studies cited in the review.
Source
Delayed gastric emptying induced by glucagon-like peptide-1 receptor agonists and its implications for perioperative risk during anesthesia
Donghee Kang et al. · The Korean Journal of Internal Medicine · 2026
DOI 10.3904/kjim.2025.277
More from this paper
- Current clinical guidelines recommend individualized perioperative management for GLP-1 RA users, with recent consensus shifting from mandatory discontinuation to risk-based assessment based on gastrointestinal symptoms and treatment duration.Good
- GLP-1 receptor agonists delay gastric emptying via peripheral and central nervous system pathways, creating a significant risk of retained gastric contents and pulmonary aspiration during anesthesia even when standard preoperative fasting guidelines are followed.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →